alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Amplification'],"[{'ncitCode': 'C1723', 'drugName': 'Cetuximab'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 933, 'code': '', 'color': 'LightSkyBlue', 'name': '', 'mainType': {'id': None, 'name': 'Esophagogastric Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Esophagus/Stomach', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23594787', '35349370', '23594786']",[],"Cetuximab and panitumumab are orally available anti-EGFR monoclonal antibodies that are FDA-approved for patients with EGFR-expressing, RAS-wildtype colorectal cancer. In a retrospective analysis, patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA) treated with EGFR inhibitors (n=60) (cetuximab [n=27; 45%], ABT-806 [n=13; 22%], panitumumab [n=10; 17%], gefitinib [n=5; 8%], erlotinib [n=3; 5%], cetuximab plus afatinib [n=1; 2%] and cetuximab plus erlotinib [n=1; 2%]) were analyzed across treatment lines, and their outcomes compared to patients with EGFR-amplified GEA treated with non-EGFR inhibitor therapies (PMID: 35349370). Patients treated with EGFR inhibitors across treatments lines (n=56) demonstrated an objective response rate of 43% (24/56) and a median progression-free survival (PFS) of 4.6 months (95% CI=3.5, 6.4) (PMID: 35349370). Among the responders (n-24), 57% (16/28) of patients received concurrent chemotherapy and 29% (8/28) of patients were treated with EGFR inhibitors alone. Patients treated with EGFR inhibitors as a first-line therapy demonstrated a median PFS of 20.6 months (95% CI=13.5, NR), whereas patients treated with non-EGFR inhibitors as a first-line therapy demonstrated a median PFS of 11.2 months (95% CI=8.7, 14.2; this data was taken from the Flatiron Health-Foundation Medicine clinicogenomic database) (PMID: 35349370). In the Phase III EXPAND trial of cetuximab plus capecitabine-cisplatin chemotherapy in patients with advanced GEA, patients with the top 3% EGFR expression based on EGFR IHC (≥220) treated with cetuximab plus capecitabine-cisplatin chemotherapy demonstrated a median PFS of 7.5 months and a median overall survival (OS) of 19.9 months whereas the placebo plus capecitabine-cisplatin chemotherapy arm demonstrated a median PFS of 4.1 months (HR=0.29 [95% CI=0.09, 0.96]) and a median OS of 8.6 months (HR=0.39 [95% CI=0.12, 1.25]) (PMID: 23594786). In the Phase III REAL3 trial of panitumumab plus epirubicin, oxaliplatin and capecitabine in patients with previously untreated advanced GEA, patients with EGFR:CNTNAP2 copy number ratio ≥5 based on EGFR FISH were treated with panitumumab plus epirubicin, oxaliplatin and capecitabine demonstrated a median PFS of 2.3 months and a median OS of 5.69 months whereas the placebo plus epirubicin, oxaliplatin and capecitabine arm demonstrated a median progression-free survival of 4.57 months (HR=2.19 [95% CI=0.8, 6.01]) and a median OS of 10.53 months (HR=1.26 [95% CI=0.46, 3.44]) (PMID: 23594787)."
['Amplification'],"[{'ncitCode': 'C1723', 'drugName': 'Cetuximab'}, {'ncitCode': 'C15632', 'drugName': 'Chemotherapy'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 933, 'code': '', 'color': 'LightSkyBlue', 'name': '', 'mainType': {'id': None, 'name': 'Esophagogastric Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Esophagus/Stomach', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23594787', '35349370', '23594786']",[],"Cetuximab and panitumumab are orally available anti-EGFR monoclonal antibodies that are FDA-approved for patients with EGFR-expressing, RAS-wildtype colorectal cancer. In a retrospective analysis, patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA) treated with EGFR inhibitors (n=60) (cetuximab [n=27; 45%], ABT-806 [n=13; 22%], panitumumab [n=10; 17%], gefitinib [n=5; 8%], erlotinib [n=3; 5%], cetuximab plus afatinib [n=1; 2%] and cetuximab plus erlotinib [n=1; 2%]) were analyzed across treatment lines, and their outcomes compared to patients with EGFR-amplified GEA treated with non-EGFR inhibitor therapies (PMID: 35349370). Patients treated with EGFR inhibitors across treatments lines (n=56) demonstrated an objective response rate of 43% (24/56) and a median progression-free survival (PFS) of 4.6 months (95% CI=3.5, 6.4) (PMID: 35349370). Among the responders (n-24), 57% (16/28) of patients received concurrent chemotherapy and 29% (8/28) of patients were treated with EGFR inhibitors alone. Patients treated with EGFR inhibitors as a first-line therapy demonstrated a median PFS of 20.6 months (95% CI=13.5, NR), whereas patients treated with non-EGFR inhibitors as a first-line therapy demonstrated a median PFS of 11.2 months (95% CI=8.7, 14.2; this data was taken from the Flatiron Health-Foundation Medicine clinicogenomic database) (PMID: 35349370). In the Phase III EXPAND trial of cetuximab plus capecitabine-cisplatin chemotherapy in patients with advanced GEA, patients with the top 3% EGFR expression based on EGFR IHC (≥220) treated with cetuximab plus capecitabine-cisplatin chemotherapy demonstrated a median PFS of 7.5 months and a median overall survival (OS) of 19.9 months whereas the placebo plus capecitabine-cisplatin chemotherapy arm demonstrated a median PFS of 4.1 months (HR=0.29 [95% CI=0.09, 0.96]) and a median OS of 8.6 months (HR=0.39 [95% CI=0.12, 1.25]) (PMID: 23594786). In the Phase III REAL3 trial of panitumumab plus epirubicin, oxaliplatin and capecitabine in patients with previously untreated advanced GEA, patients with EGFR:CNTNAP2 copy number ratio ≥5 based on EGFR FISH were treated with panitumumab plus epirubicin, oxaliplatin and capecitabine demonstrated a median PFS of 2.3 months and a median OS of 5.69 months whereas the placebo plus epirubicin, oxaliplatin and capecitabine arm demonstrated a median progression-free survival of 4.57 months (HR=2.19 [95% CI=0.8, 6.01]) and a median OS of 10.53 months (HR=1.26 [95% CI=0.46, 3.44]) (PMID: 23594787)."
['Amplification'],"[{'ncitCode': 'C1857', 'drugName': 'Panitumumab'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 933, 'code': '', 'color': 'LightSkyBlue', 'name': '', 'mainType': {'id': None, 'name': 'Esophagogastric Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Esophagus/Stomach', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23594787', '35349370', '23594786']",[],"Cetuximab and panitumumab are orally available anti-EGFR monoclonal antibodies that are FDA-approved for patients with EGFR-expressing, RAS-wildtype colorectal cancer. In a retrospective analysis, patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA) treated with EGFR inhibitors (n=60) (cetuximab [n=27; 45%], ABT-806 [n=13; 22%], panitumumab [n=10; 17%], gefitinib [n=5; 8%], erlotinib [n=3; 5%], cetuximab plus afatinib [n=1; 2%] and cetuximab plus erlotinib [n=1; 2%]) were analyzed across treatment lines, and their outcomes compared to patients with EGFR-amplified GEA treated with non-EGFR inhibitor therapies (PMID: 35349370). Patients treated with EGFR inhibitors across treatments lines (n=56) demonstrated an objective response rate of 43% (24/56) and a median progression-free survival (PFS) of 4.6 months (95% CI=3.5, 6.4) (PMID: 35349370). Among the responders (n-24), 57% (16/28) of patients received concurrent chemotherapy and 29% (8/28) of patients were treated with EGFR inhibitors alone. Patients treated with EGFR inhibitors as a first-line therapy demonstrated a median PFS of 20.6 months (95% CI=13.5, NR), whereas patients treated with non-EGFR inhibitors as a first-line therapy demonstrated a median PFS of 11.2 months (95% CI=8.7, 14.2; this data was taken from the Flatiron Health-Foundation Medicine clinicogenomic database) (PMID: 35349370). In the Phase III EXPAND trial of cetuximab plus capecitabine-cisplatin chemotherapy in patients with advanced GEA, patients with the top 3% EGFR expression based on EGFR IHC (≥220) treated with cetuximab plus capecitabine-cisplatin chemotherapy demonstrated a median PFS of 7.5 months and a median overall survival (OS) of 19.9 months whereas the placebo plus capecitabine-cisplatin chemotherapy arm demonstrated a median PFS of 4.1 months (HR=0.29 [95% CI=0.09, 0.96]) and a median OS of 8.6 months (HR=0.39 [95% CI=0.12, 1.25]) (PMID: 23594786). In the Phase III REAL3 trial of panitumumab plus epirubicin, oxaliplatin and capecitabine in patients with previously untreated advanced GEA, patients with EGFR:CNTNAP2 copy number ratio ≥5 based on EGFR FISH were treated with panitumumab plus epirubicin, oxaliplatin and capecitabine demonstrated a median PFS of 2.3 months and a median OS of 5.69 months whereas the placebo plus epirubicin, oxaliplatin and capecitabine arm demonstrated a median progression-free survival of 4.57 months (HR=2.19 [95% CI=0.8, 6.01]) and a median OS of 10.53 months (HR=1.26 [95% CI=0.46, 3.44]) (PMID: 23594787)."
['Amplification'],"[{'ncitCode': 'C1857', 'drugName': 'Panitumumab'}, {'ncitCode': 'C15632', 'drugName': 'Chemotherapy'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 933, 'code': '', 'color': 'LightSkyBlue', 'name': '', 'mainType': {'id': None, 'name': 'Esophagogastric Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Esophagus/Stomach', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['23594787', '35349370', '23594786']",[],"Cetuximab and panitumumab are orally available anti-EGFR monoclonal antibodies that are FDA-approved for patients with EGFR-expressing, RAS-wildtype colorectal cancer. In a retrospective analysis, patients with EGFR-amplified gastroesophageal adenocarcinoma (GEA) treated with EGFR inhibitors (n=60) (cetuximab [n=27; 45%], ABT-806 [n=13; 22%], panitumumab [n=10; 17%], gefitinib [n=5; 8%], erlotinib [n=3; 5%], cetuximab plus afatinib [n=1; 2%] and cetuximab plus erlotinib [n=1; 2%]) were analyzed across treatment lines, and their outcomes compared to patients with EGFR-amplified GEA treated with non-EGFR inhibitor therapies (PMID: 35349370). Patients treated with EGFR inhibitors across treatments lines (n=56) demonstrated an objective response rate of 43% (24/56) and a median progression-free survival (PFS) of 4.6 months (95% CI=3.5, 6.4) (PMID: 35349370). Among the responders (n-24), 57% (16/28) of patients received concurrent chemotherapy and 29% (8/28) of patients were treated with EGFR inhibitors alone. Patients treated with EGFR inhibitors as a first-line therapy demonstrated a median PFS of 20.6 months (95% CI=13.5, NR), whereas patients treated with non-EGFR inhibitors as a first-line therapy demonstrated a median PFS of 11.2 months (95% CI=8.7, 14.2; this data was taken from the Flatiron Health-Foundation Medicine clinicogenomic database) (PMID: 35349370). In the Phase III EXPAND trial of cetuximab plus capecitabine-cisplatin chemotherapy in patients with advanced GEA, patients with the top 3% EGFR expression based on EGFR IHC (≥220) treated with cetuximab plus capecitabine-cisplatin chemotherapy demonstrated a median PFS of 7.5 months and a median overall survival (OS) of 19.9 months whereas the placebo plus capecitabine-cisplatin chemotherapy arm demonstrated a median PFS of 4.1 months (HR=0.29 [95% CI=0.09, 0.96]) and a median OS of 8.6 months (HR=0.39 [95% CI=0.12, 1.25]) (PMID: 23594786). In the Phase III REAL3 trial of panitumumab plus epirubicin, oxaliplatin and capecitabine in patients with previously untreated advanced GEA, patients with EGFR:CNTNAP2 copy number ratio ≥5 based on EGFR FISH were treated with panitumumab plus epirubicin, oxaliplatin and capecitabine demonstrated a median PFS of 2.3 months and a median OS of 5.69 months whereas the placebo plus epirubicin, oxaliplatin and capecitabine arm demonstrated a median progression-free survival of 4.57 months (HR=2.19 [95% CI=0.8, 6.01]) and a median OS of 10.53 months (HR=1.26 [95% CI=0.46, 3.44]) (PMID: 23594787)."
['Amplification'],"[{'ncitCode': 'C26653', 'drugName': 'Lapatinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 882, 'code': '', 'color': 'Gray', 'name': '', 'mainType': {'id': None, 'name': 'Glioma', 'tumorForm': 'SOLID'}, 'tissue': 'CNS/Brain', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['22588883', '20459769', '18334972']",[],"Lapatinib is a small molecule tyrosine kinase inhibitor of the ERBB2 and EGFR kinases. In vitro studies of glioma cell lines expressing EGFR ectodomain mutations demonstrated that they were sensitive to treatment with lapatinib as shown by apoptosis and decreased pathway activation upon drug treatment. Lapatinib sensitivity has also been observed in lung cancer cell lines with EGFR ectodomain mutations or EGFR amplification, and in endometrial cancer cell lines with increased EGFR expression (PMID: 22588883, 20459769, 18334972)."
